Other Events ·
Sarepta pays $39M to settle patent infringement litigation with REGENXBIO and University of Pennsylvania
SRPTSarepta Therapeutics, Inc.
Sarepta Therapeutics entered into a settlement agreement on September 23, 2026, resolving pending patent infringement litigations and inter partes review appeals with REGENXBIO Inc. and the University of Pennsylvania regarding U.S. Patent Nos. 11,680,274 and 10,526,617. Sarepta paid a lump sum of $39.0 million to REGENXBIO within ten days of the effective date. The agreement includes a release of claims related to AAVrh74-based capsid gene therapies, including ELEVIDYS, and prohibits future suits by REGENXBIO regarding these patents for existing products. Sarepta operates in the biotechnology industry, specializing in genetic medicines.